

Supplementary table

Supplementary Table 2. Absolute change of each lipid profiles (analysis was limited to 828 patients who did not take statins at the time of enrollment)

| | Baseline | 3 months | P value |
|---------------------------|-----------|-----------|---------|
| Total cholesterol (mg/dl) | | | |
| Pitavastatin mono-therapy | 215±36.2 | 161±28.3 | <.0001 |
| Pitavastatin + ezetimibe | 212±34.1 | 138±26.2 | <.0001 |
| HDL cholesterol (mg/dl) | | | |
| Pitavastatin mono-therapy | 48.5±13.2 | 48.5±12.4 | 0.97 |
| Pitavastatin + ezetimibe | 48.0±12.7 | 49.0±11.5 | 0.07 |
| LDL cholesterol (mg/dl) | | | |
| Pitavastatin mono-therapy | 139±30.0 | 83.3±22.3 | <.0001 |
| Pitavastatin + ezetimibe | 137±28.7 | 63.0±20.5 | <.0001 |
| Triglyceride (mg/dl) | | | |
| Pitavastatin mono-therapy | 135±72.7 | 153±98.1 | 0.0001 |
| Pitavastatin + ezetimibe | 130±66.4 | 130±71.7 | 0.95 |
| EPA (µg/ml) | | | |
| Pitavastatin mono-therapy | 61.5±33.5 | 70.5±45.9 | <.0001 |
| Pitavastatin + ezetimibe | 56.6±29.3 | 59.9±39.4 | 0.06 |

| | | | |
|---------------------------|-----------|-----------|--------|
| AA (µg/ml) | | | |
| Pitavastatin mono-therapy | 165±43.5 | 165±44.7 | 0.76 |
| Pitavastatin + ezetimibe | 165±43.6 | 170±45.6 | 0.006 |
| EPA/AA | | | |
| Pitavastatin mono-therapy | 0.40±0.25 | 0.46±0.34 | <.0001 |
| Pitavastatin + ezetimibe | 0.36±0.20 | 0.37±0.25 | 0.2 |

A total of 412 patients were received pitavastatin mono-therapy and a total of 416 patients were received pitavastatin + ezetimibe therapy

p-value refers to the difference between baseline and 3-month follow-up by a paired t-test.

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; EPA, eicosapentaenoic acid; AA, arachidonic acid.

*Data are expressed as mean ± SD